May 14,2020

Research published at ASCO 2020 shows that machine learning models trained with patient-reported data can predict onset and presence of immune-related adverse events

The cooperative research between Kaiku Health and Oulu University Hospital aimed to investigate whether patient-reported symptom data (Patient-Reported Outcomes) could be used as an input for machine learning-based prediction models for early detection of immune-related adverse events (irAEs). The research was published at ASCO Annual Meeting 2020 Online Publication on the 13th of May, 2020. The results suggest that machine learning-based prediction models, using patient-reported symptom data as input for the models, can predict the presence and onset of irAEs with high accuracy.

CLINICAL STUDY

#platform

#ml

View Analyst & Ambassador Comments
Go to original news
May 19,2020

Acquisition of Kaiku Health strengthens Elekta Digital offering with personalized digital health interventions

Elekta (EKTA-B.ST) announced today that it will further develop its focus on cancer care providers and their patients through its acquisition of Kaiku Health. The Finnish company is best known for its app that monitors patient-reported outcomes, providing intelligent symptom tracking and management for healthcare providers in routine oncology care and studies. The Kaiku Health app screens for patients’ symptoms, notifies the care team on their development and provides value-based personalized support for patients. It is easily implemented into existing hospital information systems and can be integrated with Elekta’s MOSAIQ® Oncology Information System (OIS).

COLLABORATION MERGERS & ACQUISITION

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 28,2020

Carevive Launches OPT-IN – Building the Largest Real-World Cancer Patient Experience Database

Carevive Systems, a leading oncology-focused health technology company, announced today that it has launched the Carevive Oncology Pragmatic Trials Investigator Network (Carevive OPT-IN®). This consortium of physician-researchers is collecting Patient Experience Data using Carevive’s digital platform in the following cancer types: lung cancer, breast cancer, ovarian cancer, and multiple myeloma. Carevive OPT-IN® is a novel and unique real-world Patient Experience Database consisting of EHR-derived clinical data and longitudinal Patient-Reported Outcomes (PRO). Together, this combination presents the most comprehensive picture of real-world symptoms of disease and treatment in cancer.

PRODUCT

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
May 05,2020

OncoHealth Partners with Gateway Health to Provide Data-Driven Solution for Medical Oncology

OncoHealth is currently managing Gateway’s Medicare population for oncology prior authorization requests and will begin managing its Medicaid population later this year. This includes outpatient, anti-cancer, and supportive care drugs within both the medical and pharmacy care benefit. By combining the reviews of both the pharmacy benefit drugs with the medical benefit drugs, Gateway members are assured of a more complete assessment of their care. Providers participating in Gateway’s network can also conveniently access the OncoHealth platform through single sign-on, using the same credentials they use for the Gateway Provider Portal. In partnering with OncoHealth, Gateway will also gain access to Oncology Insights™, a real-world data analytics solution that combines clinical oncology data with Gateway’s health plan data.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
May 26,2020

OncoHealth Raises $28 Million Series C Financing Led by Baird Capital

OncoHealth, the leading digital health company focused on the physical, mental and financial complexities of cancer care, and patients with solutions that are purpose-built for oncology, has announced the completion of a Series C funding round of $28M. Baird Capital led the round and joins existing investors Oak HC/FT, McKesson Ventures, and The Blue Venture Fund.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
May 15,2020

A Real-Life Example of a Telehealth Cancer Genetic Screening Program

Fewer Americans have been getting cancer screenings like colonoscopies, mammograms and Pap smears since COVID-19 forced many clinics to put restrictions in place. Dr. Westgate founded the Adventist Health Early All-Around Detection (AHEAD) program to help prevent cancer diagnoses and didn’t want COVID-19 to derail the program’s work. Instead of filling out family and personal history forms in-person on a tablet, patients get an email request ahead of their virtual appointment to fill out the forms. CancerIQ then flags patients who are at increased risk of cancer based on their history.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 01,2020

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2020 Annual Meeting

Flatiron Health today announced eight abstracts were accepted for presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29–31.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 01,2020

Flatiron Health, Foundation Medicine and Genentech Partner to Launch Novel Prospective Lung Cancer Clinical Study

Flatiron Health, Foundation Medicine, and Genentech, a member of the Roche Group, in partnership with community and academic oncology practices, have launched the Prospective Clinico-Genomic (PCG) Study, NCT04180176. PCG is a novel, low-interventional study that will pilot the use of a technology-enabled prospective data collection platform to facilitate, streamline and simplify the execution of clinical trials for patients living with advanced lung cancer.

COLLABORATION PARTNERSHIP

#r&d

#rwd

View Analyst & Ambassador Comments
Go to original news
May 14,2020

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings

Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25thCongress of the European Hematology Association (EHA25; June 11 – 14).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 14,2020

Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

Data from more than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented during the upcoming American Society of Clinical Oncology ASCO20 Virtual Scientific Program and the European Hematology Association EHA25 Virtual Congress. The ASCO and EHA meetings will be held May 29-31, and June 11-14, respectively.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY